Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer

Abstract

The present invention relates to a pharmaceutical combination comprising (i) at least one nucleic acid comprising an antisense and flipped sequence of a fragment of a sequence coding for a kanamycin resistance protein, (ii) at least one non-immuno-suppressive inducer of tumor cell apoptosis and (iii) at least one checkpoint inhibitor. Said nucleic acid is preferably pVAX14 plasmid, said non-immunosuppressive inducer of tumor cell apoptosis is preferably ATRA or an arsenic-related compound and said checkpoint inhibitor is preferably an anti-PD1 or anti-CD47 antibody or a fragment thereof. The present invention also relates to the pharmaceutical combination as defined above for use in the treatment of cancer, in particular of breast cancer to slow or stop the development of cancer.

Dependencies are inferred from the claim text.